Year Founded
2011
Ownership
Private
Employees
~50
Therapeutic Areas
CardiovascularRheumatologyImmunologyNeurologyInfectious Diseases
Stage
Commercial
Modalities
Mesenchymal stem cell therapyExosome therapy

Celltex Therapeutics General Information

Over 10,000 stem cell therapies administered. Multiple successful patient cases reported for various conditions. No FDA approved products in US, but approved products in other countries.

Contact Information

Website
Primary Industry
[ "Biotech" ]
Corporate Office
Houston, Texas
United States

Drug Pipeline

Celltex MSCs
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Celltex Therapeutics's pipeline data

Book a demo

Key Partnerships

Saudi Arabia's Research Products Development Company (RPDC), BioSolution Designs, RoosterBio

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Celltex Therapeutics Funding

Deal TypeDateAmountStatusStage
Later Stage VCJul 6, 2012$34.1MCompletedCommercial
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Celltex Therapeutics's complete valuation and funding history, request access »

Celltex Therapeutics Investors

Paycheck Protection Program
Investor Type: Venture Capital
Holding: Minority